284 Diagnostic value of fibrosis biochemical markers (fibrotest) for the screening of oesophageal varices in patients with chronic liver disease

Thabut, D.; Trabut, Jean‐Baptiste; Lecalvez, S; Thibaut, V; Massard, Julien; Darondel, C; Moussalli, J.; Munteanu, Mona; Imbert‐Bismut, Françoise; Messous, Djamila

doi:10.1016/s0270-9139(03)80327-0

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between February 2001 and March 2004, a total of 16 publications 8,9 , 11–21,27–29 and four abstracts without corresponding publications were identified 30–33 …”

Section: Resultsmentioning

confidence: 99%

Biomarkers as non‐invasive assessment of hepatic fibrosis in chronic hepatitis C

Poynard

Imbert‐Bismut

Munteanu

et al. 2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

Liver biopsy has been considered as the gold standard for assessing the stage and the grade of chronic liver diseases. Biopsy has a high sampling error (33% for fibrosis staging and 24% for necrosis staging), and intra-and interpathologist variability greater than 10%. Biochemical markers, particularly recent panels of markers (FibroTest-ActiTest) have good predictive values with a better benefit risk ratio and lower cost than liver biopsy. Discordances between biopsy and serological markers results can be either due to serological markers or to biopsy. Because of the improvement of biochemical markers, the limits and the risk of biopsy, liver biopsy should not be mandatory any longer in the management of patients with chronic liver hepatitis C.

show abstract

“…Between February 2001 and March 2004, a total of 16 publications 8,9 , 11–21,27–29 and four abstracts without corresponding publications were identified 30–33 …”

Section: Resultsmentioning

confidence: 99%

Biomarkers as non‐invasive assessment of hepatic fibrosis in chronic hepatitis C

Poynard

Imbert‐Bismut

Munteanu

et al. 2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Diagnosis and treatment of viral liver fibrosis

Poynard

Imbert‐Bismut

Munteanu

et al. 2005

Saudi J Gastroenterol

View full text Add to dashboard Cite

This review summarized the diagnostic value of fibrosis biomarkers and the efficacy of anti-viral treatments on fibrosis progression. Non-invasive biomarkers can facilitate the screening and management of chronic hepatitis C and B. Screening for significant fibrosis is-mandatory as very effective anti-viral treatments are available, permitting to stop or to reduce the fibrosis progression. The reduction of fibrosis progression will decrease the mortality due to complications of cirrhosis. In patients with chronic hepatitis C, pegylated interferons combined with ribavirin are effective in reducing fibrosis progression. In patients with chronic hepatitis B, lamivudine, adefovir and pegylated interferon are also effective in reducing fibrosis progression. In patients with chronic hepatitis Delta, pegylated interferon is also effective in reducing fibrosis progression.

show abstract

284 Diagnostic value of fibrosis biochemical markers (fibrotest) for the screening of oesophageal varices in patients with chronic liver disease

Cited by 2 publications

References 0 publications

Biomarkers as non‐invasive assessment of hepatic fibrosis in chronic hepatitis C

Biomarkers as non‐invasive assessment of hepatic fibrosis in chronic hepatitis C

Diagnosis and treatment of viral liver fibrosis

Contact Info

Product

Resources

About